Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Harvard Business School
McKesson
Colorcon
Dow

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR XALKORI


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Xalkori

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed Pfizer Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed Children's Oncology Group Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT01531361 ↗ Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Completed National Cancer Institute (NCI) Phase 1 2012-02-06 This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xalkori

Condition Name

Condition Name for Xalkori
Intervention Trials
Advanced Malignant Solid Neoplasm 4
Carcinoma, Non-Small-Cell Lung 4
Refractory Malignant Solid Neoplasm 4
Advanced Cancers 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xalkori
Intervention Trials
Carcinoma, Non-Small-Cell Lung 18
Lung Neoplasms 14
Neoplasms 12
Lymphoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xalkori

Trials by Country

Trials by Country for Xalkori
Location Trials
United States 543
China 51
Japan 27
Canada 24
Italy 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xalkori
Location Trials
Texas 20
New York 19
Pennsylvania 18
California 17
Florida 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xalkori

Clinical Trial Phase

Clinical Trial Phase for Xalkori
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xalkori
Clinical Trial Phase Trials
Recruiting 17
Active, not recruiting 11
Completed 9
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xalkori

Sponsor Name

Sponsor Name for Xalkori
Sponsor Trials
Pfizer 23
National Cancer Institute (NCI) 14
M.D. Anderson Cancer Center 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xalkori
Sponsor Trials
Industry 58
Other 43
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.